Current Therapeutic Approaches for Gravesʼ Orbitopathy – are Targeted Therapies the Future?
Klinische Monatsblätter für Augenheilkunde · 01.01.2024 · 241 (01) · 48-68
DOI: 10.1055/a-2186-5548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.01.2024. Verfasst von Anja Eckstein und 6 weiteren Autor:innen. Beteiligte Einrichtung: Klinik für Augenheilkunde, Universitätsklinikum Essen, Deutschland. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Graves Disease, Hyperthyroidism, Exophthalmos. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 181 Literaturangaben.
Abstract (Originalsprache)
Gravesʼ orbitopathy is an autoimmune disease of the orbit that most frequently occurs with Gravesʼ hyperthyroidism. The occurrence of autoantibodies directed against the TSH receptor (TRAb) is of central importance for the diagnosis and pathogenesis. These autoantibodies are mostly stimulating, and induce uncontrolled hyperthyroidism and tissue remodelling in the orbit and more or less pronounced inflammation. Consequently, patients suffer to a variable extent from periocular swelling, exophthalmos, and fibrosis of the eye muscles and thus restrictive motility impairment with double vision. In recent decades, therapeutic approaches have mainly comprised immunosuppressive treatments and antithyroid drug therapy for hyperthyroidism to inhibit thyroid hormone production. With the recognition that TRAb also activates an important growth factor receptor, IGF1R (insulin-like growth factor 1 receptor), biological agents have been developed. Teprotumumab (an inhibitory IGF1R antibody) has already been approved in the USA and the therapeutic effects are enormous, especially with regard to the reduction of exophthalmos. Side effects are to be considered, especially hyperglycaemia and hearing loss. It is not yet clear whether the autoimmune reaction (development of the TRAb/attraction of immunocompetent cells) is also influenced by anti-IGF1R inhibiting agents. Recurrences after therapy show that the inhibition of antibody development must be included in the therapeutic concept, especially in severe cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Klinik für Augenheilkunde, Universitätsklinikum Essen, Deutschland.
- Labor für Molekulare Augenheilkunde, Universität Duisburg-Essen, Duisburg, Deutschland.
- Klinik für Endokrinologie, Diabetologie und Stoffwechsel, Universitätsklinikum Essen, Deutschland.
- Gemeinschaftspraxis Dres. Oeverhaus & Weiß, Rietberg, Deutschland.
Zitieren
APA
Eckstein, A., Stöhr, M., Görtz, G. E., Gulbins, A., Möller, L., Fuehrer-Sakel, D., & Oeverhaus, M. (2024). Current Therapeutic Approaches for Gravesʼ Orbitopathy – are Targeted Therapies the Future?. Klinische Monatsblätter für Augenheilkunde, 241(01), 48-68. https://doi.org/10.1055/a-2186-5548
Vancouver
Eckstein A, Stöhr M, Görtz GE, Gulbins A, Möller L, Fuehrer-Sakel D, et al. Current Therapeutic Approaches for Gravesʼ Orbitopathy – are Targeted Therapies the Future?. Klinische Monatsblätter für Augenheilkunde. 2024;241(01):48-68. doi:10.1055/a-2186-5548
BibTeX
@article{Eckstein2024,
author = {Eckstein, Anja and Stöhr, Mareile and Görtz, Gina-Eva and Gulbins, Anne and Möller, Lars and Fuehrer-Sakel, Dagmar and Oeverhaus, Michael},
title = {Current Therapeutic Approaches for Gravesʼ Orbitopathy – are Targeted Therapies the Future?},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2024},
volume = {241},
number = {01},
pages = {48--68},
doi = {10.1055/a-2186-5548}
}
EUVIMED